Pirarubicin combined with TLR3 or TLR4 agonists enhances anti-tumor efficiency.
Zhang R, Cui NP, He Y, Wang T, Feng D, Wang Y, Bao T, Su C, Qin Y, Shi JH, Li JH.
Zhang R, et al. Among authors: shi jh.
Int Immunopharmacol. 2024 Dec 5;142(Pt A):113068. doi: 10.1016/j.intimp.2024.113068. Epub 2024 Sep 5.
Int Immunopharmacol. 2024.
PMID: 39241516